TAK 1 at the crossroads of multiple regulated cell death pathways: from molecular mechanisms to human diseases
The FEBS Journal · 2025
DOI: 10.1111/febs.70042 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FEBS Journal, 2025. Verfasst von Kun Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha, China. Hauptthemen laut MEDLINE: MAP Kinase Kinase Kinases, Neoplasms, Regulated Cell Death. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 265 Literaturangaben. Gefördert von: Key Laboratory of Emergency and Trauma (Hainan Medical University) of Ministry of Education, China, Natural Science Foundation of Hunan Province, China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Regulated cell death (RCD), the form of cell death that can be genetically controlled by multiple signaling pathways, plays an important role in organogenesis, tissue remodeling, and maintenance of organism homeostasis and is closely associated with various human diseases. Transforming growth factor‐beta‐activated kinase 1 (TAK1) is a member of the serine/threonine protein kinase family, which can respond to different internal and external stimuli and participate in inflammatory and immune responses. Emerging evidence suggests that TAK1 is an important regulator at the crossroad of multiple RCD pathways, including apoptosis, necroptosis, pyroptosis, and PANoptosis. The regulation of TAK1 affects disease progression through multiple signaling pathways, and therapeutic strategies targeting TAK1 have been proposed for inflammatory diseases, central nervous system diseases, and cancers. In this review, we provide an overview of the downstream signaling pathways regulated by TAK1 and its binding proteins. Their critical regulatory roles in different forms of cell death are also summarized. In addition, we discuss the potential of targeting TAK1 in the treatment of human diseases, with a specific focus on neurological disorders and cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha, China.
- Xiangya School of Medicine, Central South University, Changsha, China.
- Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA.
- Key Laboratory of Emergency and Trauma of Ministry of Education, College of Emergency and Trauma, Hainan Medical University, Haikou, China.
- Department of Endocrinology, Third Xiangya Hospital, Central South University, Changsha, China.
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA, USA.
Förderung
- Key Laboratory of Emergency and Trauma (Hainan Medical University) of Ministry of Education, China
- Natural Science Foundation of Hunan Province, China
- National Natural Science Foundation of China
- Hainan Medical University
- Natural Science Foundation of Hunan Province
Zitieren
APA
Huang, K., Zhang, Q., Wan, H., Ban, X. X., Chen, X. Y., Wan, X. X., Lu, R., He, Y., & Xiong, K. (2025). TAK 1 at the crossroads of multiple regulated cell death pathways: from molecular mechanisms to human diseases. The FEBS Journal. https://doi.org/10.1111/febs.70042
Vancouver
Huang K, Zhang Q, Wan H, Ban XX, Chen XY, Wan XX, et al. TAK 1 at the crossroads of multiple regulated cell death pathways: from molecular mechanisms to human diseases. The FEBS Journal. 2025. doi:10.1111/febs.70042
BibTeX
@article{Huang2025,
author = {Huang, Kun and Zhang, Qi and Wan, Hao and Ban, Xiao-Xia and Chen, Xin-Yu and Wan, Xin-Xing and Lu, Rui and He, Ye and Xiong, Kun},
title = {TAK 1 at the crossroads of multiple regulated cell death pathways: from molecular mechanisms to human diseases},
journal = {The FEBS Journal},
year = {2025},
doi = {10.1111/febs.70042}
}
EUVIMED